Citi Pharma Limited reported a net profit of Rs 883 million for the nine months ended March 31, 2026
Filed as: Financial Results for the Quarter Ended 31 March 2026
Summary
Citi Pharma Limited reported a net profit of Rs 883 million for the nine months ended March 31, 2026, with net sales reaching Rs 10.79 billion. The company showed a notable increase in profitability despite a decrease in cash and cash equivalents.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Net Profit | PKR 883.44M | PKR 678.84M | +30.1% |
| Net Sales | PKR 10,787.56M | PKR 10,100.19M | +6.8% |
| Cash and Cash Equivalents | PKR 321.07M | PKR 1,227.38M | -73.8% |
| Earnings Per Share (EPS) | 3.87 | 2.97 | +30.3% |
| Operating Profit | PKR 1,654.76M | PKR 1,174.71M | +40.9% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Net profit increased to Rs 883 million, up from Rs 679 million in the prior period, marking a growth of 30.12%.
- Net sales rose to Rs 10.79 billion, a 6.81% increase from Rs 10.10 billion in the prior period.
- Cash and cash equivalents decreased significantly to Rs 321 million from Rs 1.23 billion, indicating a reduction in liquidity.
Citi Pharma Ltd. (CPHL) on Nafa
Last price Rs 64.00 · Pharmaceuticals · You can own CPHL shares from your phone.
More CPHL announcements
- NoticeTransmission of Quarterly Report for the Period Ended 30 September 2026
- Financial resultCiti Pharma Limited reported a net profit of Rs 233.23 million for the period ended September 30, 2026Filed as: Financial Results for the Quarter Ended 30 September 2026
- NoticeBoard Meeting In Progress
- Material informationCiti Pharma Acquires 20% of Pakheim InternationalCiti Pharma Limited acquires 20% shareholding in Pakheim International Pharma, marking the first step towards full acquisition.
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeChange of Chief Financial Officer
Source: Citi Pharma Ltd.'s filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.